Belnacasan (VX765)
Belnacasan, also known as VX-765, is designed to inhibit Caspase, which is an enzyme that controls the generation of two cytokines, IL-1b and IL-18. VX-765 has been shown to inhibit acute seizures in preclinical models. In addition, VX-765 has shown activity in preclinical models of chronic epilepsy. VX-765 had been dosed in over 100 patients in phase-I and phase-IIa clinical trials relating to other diseases, including a 28-day phase-IIa clinical trial in patients with psoriasis. It has completed the treatment phase of a phase-IIa clinical trial of VX-765 that enrolled approximately 75 patients with treatment-resistant epilepsy. The double-blind, randomized, placebo-controlled clinical trial was designed to evaluate the safety, tolerability and clinical activity of VX-765.
| Supplier | Ace Therapeutics |
|---|---|
| Product # | SMD713 |
| CAS # | 273404-37-8 |
| Pricing | Customizable size, Inquiry |
| Synonym | VX 765, VX765, VX-765, Belnacasan |
| Product Category | Lab-use Small Molecule Drugs |
| Chemical Formula | C24H33ClN4O6 |
| Exact Mass | 508.20886 |
| Molecular Weight | 508.99 |
| Elemental Analysis | C, 56.63; H, 6.53; Cl, 6.97; N, 11.01; O, 18.86 |
| IUPAC/Chemical Name | (S)-1-((S)-2-(4-amino-3-chlorobenzamido)-3,3-dimethylbutanoyl)-N-((2R,3S)-2-ethoxy-5-oxotetrahydrofuran-3-yl)pyrrolidine-2-carboxamide |
| InChi Key | SJDDOCKBXFJEJB-MOKWFATOSA-N |
| InChi Code | InChI=1S/C24H33ClN4O6/c1-5-34-23-16(12-18(30)35-23)27-21(32)17-7-6-10-29(17)22(33)19(24(2,3)4)28-20(31)13-8-9-15(26)14(25)11-13/h8-9,11,16-17,19,23H,5-7,10,12,26H2,1-4H3,(H,27,32)(H,28,31)/t16-,17-,19+,23+/m0/s1 |
| SMILES Code | O=C([C@H]1N(C([C@@H](NC(C2=CC=C(N)C(Cl)=C2)=O)C(C)(C)C)=O)CCC1)N[C@@H](C3)[C@H](OCC)OC3=O |
| Appearance | White to off-white solid powder |
| Purity | >98% (or refer to the Certificate of Analysis) |
| Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
| Storage Condition | 0 – 4 o C for short term (weeks to 1 month) or -20 o C for long terms (months to years). |
| Solubility | soluble in DMSO, not soluble in water. |
| Shelf Life | >2 years if stored properly. |
| Drug Formulation | This drug may be formulated in DMSO |
| Stock Solution Storage | 0 - 4℃ for short term (days to weeks), or -20℃ for long term (months). |
| HS Tariff Code | 2934.99.9001 |
| Availability | 2 Weeks |